Taysha Gene Therapies (NASDAQ:TSHA) filed a prospectus for a mixed shelf offering of up to $300 million. The preliminary prospectus is not an offer to sell. Filing Taysha Gene Therapies ...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the ...

Taysha Gene Therapies, Inc. DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on ...

Taysha Gene Therapies Stock Down 1.7 % Shares of NASDAQ:TSHA opened at $1.72 on Tuesday. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The ...

Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Avi Kapoor Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" Neurogene (NASDAQ:NGNE ...

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.35 per share a year ago.

The Japanese firm has agreed to make a $50 million investment in Dallas-based Taysha in exchange for a 15% stake in the company, plus exclusive options to license two clinical-stage, single-gene ...

DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus ...